Assessment of Complete Pathologic Response After Neoadjuvant Chemotherapy for Breast Cancer

Assessment of Complete Pathologic Response After Neoadjuvant Chemotherapy for Breast Cancer

This is a feasibility study to gain preliminary information regarding whether breast imaging with or without a core needle biopsy after neoadjuvant chemotherapy (NAC) but before surgery can accurately predict complete pathologic response (pCR) in women with triple negative or HER2- positive breast cancer. pCR is defined as having no residual invasive breast cancer or ductal carcinoma in situ.

Inclusion Criteria:

• Biopsy proven triple negative (TN) (ER-/PR-/HER2-) or HER2 positive (ERany/PRany/HER2+) breast cancer for which neoadjuvant chemotherapy is planned
• A biopsy clip placed at the time of diagnostic biopsy
• 18 years of age or older
• Must be able to read and write in English due to the importance of survey (questionnaire) completion to meet the study's endpoint - this is justified as there is no individual benefit to study participation
• Able to provide written consent prior to any research related activities

Exclusion Criteria:

• Stage IV breast cancer
• T4 breast cancer
• Previous ipsilateral breast cancer
• Any contraindication for undergoing a contrast-enhanced breast MRI and/or the breast biopsy between chemotherapy and surgery